Treatment of respiratory conditions associated with bronchoconstriction with aerosolized hyaluronic acid
OwnerWilliam M. Abraham, Mario Scuri +5inventors
InventorsWilliam M. Abraham, Mario Scuri, Rosanna Forteza, Jing-Wen Kuo, Paul Mihalko, Gregory E. Conner, Matthias Salathe
Life of this patent
Estimating the term…
Abstract
A method is disclosed for treating and/or preventing bronchoconstriction induced by neutrophil elastase and tissue kallikrein activity. The method includes administration of aerosolized hyaluronic acid in an amount sufficient to bind to RHAMM (CD168) receptors along the apical surface of the airway epithelium, wherein the hyaluronic acid binds and retains secreted tissue kallikrein, thereby treating and/or preventing bronchoconstriction due to kallikrein activity.
Claims20
A method of treating or preventing respiratory conditions associated with tissue kallikrein-induced bronchoconstriction and/or airway hyperreactivity, comprising administering to a mammal in need thereof an amount of an aerosolized formulation comprising a polysaccharide capable of binding to CD44 and/or RHAMM cell surface receptors at a location along an airway epithelium, said amount being sufficient to sequester tissue kallikrein to said location, wherein an enzymatic activity of the tissue kallikrein is inhibited, thereby treating or preventing the respiratory condition.
A method of treating or preventing respiratory conditions associated with tissue kallikrein-induced bronchoconstriction and/or airway hyperreactivity, comprising administering to a mammal in need thereof an aerosolized formulation comprising hyaluronic acid in an amount sufficient to bind to RHAMM cell surface receptors at a ciliated border of an airway epithelium and sequester tissue kallikrein to the ciliated border, thereby treating or preventing the respiratory condition.
A method for preventing acute bronchoconstriction due to an induction of neutrophil elastase, comprising administering to a mammal at least four hours prior to the induction an aerosolized formulation comprising hyaluronic acid at a concentration of at least 0.1% (w/v) with an average molecular weight of 150,000 daltons.
Dependencies are inferred from the claim text.